A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Completed · Phase 1

Conditions studied: Healthy Male Volunteers

In brief

The purpose of this study is to evaluate the excretion pathway of orally administered \[14C\]-BMS-986196 and to assess the safety and tolerability of orally administered BMS-986196.

Key facts

Study ID

NCT05981963

Run by

Bristol-Myers Squibb

People needed

8

Starts

2023-08-17

Expected to finish

2023-10-22

Last updated by the study team

2023-11-13

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male participants without clinically significant deviation from normal in medical history, electrocardiogram (ECG), clinical laboratory determinations, and Day -1 physical examination.
• Body mass index of 18.0 to 35.0 kilograms/meter square (kg/m\^2), inclusive, and total body weight ≥ 50 kg

You may not qualify if…

• Any significant acute or chronic medical illness as determined by the investigator.
• A history of clinically significant hepatic or pancreatic disease.
• Current or recent (within 3 months prior to study treatment administration) gastrointestinal disease that could impact upon the absorption, distribution, metabolism, or excretion of study treatment as determined by the investigator.
• Note: Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

• Labcorp Clinical Research Unit - Madison — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.